Epigenetics in Parkinson’s and Alzheimer’s diseases

Subcellular Biochemistry

Volumn 61, Issue , 2013, Pages 507-525

  Marques, Sueli ^a   Outeiro, Tiago Fleming ^a,b,c  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b Instituto de Fisiologia   (Portugal)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE; MICRORNA;

ALZHEIMER DISEASE; ANIMAL; CHROMATIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETICS; HUMAN; METABOLISM; PARKINSON DISEASE; PHENOTYPE; REVIEW; RISK FACTOR;

ALZHEIMER DISEASE; ANIMALS; CHROMATIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HISTONES; HUMANS; MICRORNAS; PARKINSON DISEASE; PHENOTYPE; RISK FACTORS;

EID: 84894240705     PISSN: 03060225     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-94-007-4525-4_22     Document Type: Article

References (78)

1. Agirre X, Román-Gómez J, Vázquez I, Jiménez-Velasco A, Garate L, Montiel-Duarte C, Artieda P, Cordeu L, Lahortiga I, Calasanz MJ, Heiniger A, Torres A, Minna JD, Prósper F (2006) Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia. Int J Cancer 118(8): 1945-1953.
2. Association A (2009) Alzheimer's disease facts andfigures. Alzheimers Dement 5: 234-270.
3. Bak M, Silahtaroglu A, Møller M, Christensen M, Rath MF, Skryabin B, Tommerup N, Kauppinen S (2008) MicroRNA expression in the adult mouse central nervous system. RNA 14(3): 432-444.
4. Bettens K, Sleegers K, Broeckhoven CV (2010) Current status on Alzheimer disease molecular genetics: from past, to present, to future. Hum Mol Genet 19(1): R4-R11.
5. Blandini F, Fancellu R, Martignoni E, Mangiagalli A, Pacchetti C, Samuele A, Nappi G (2001) Plasma homocysteine and l-dopa metabolism in patients with Parkinson disease. Clin Chem 47(6): 1102-1104.
6. Boissonneault V, Plante I, Rivest S, Provost P (2009) MicroRNA-298 and microRNA-328 regulate expression of mouse beta-amyloid precursor protein-converting enzyme 1. J Biol Chem 284(4): 1971-1981.
7. Bönsch D, Lenz B, Kornhuber J, Bleich S (2005) DNA hypermethylation of the alpha synuclein promoter in patients with alcoholism. Neuroreport 16(2): 167-170.
8. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurob Aging 24: 197-211.
9. Brami-Cherrier K, Valjent E, Hervé D, Darragh J, Corvol JC, Pages C, Arthur SJ, Girault JA, Caboche J (2005) Parsing molecular and behavioral effects of cocaine in mitogen-and stressactivated protein kinase-1-deficient mice. J Neurosci 25(49): 11444-11454.
10. Burke RE, Dauer, Vonsattel JPG (2008) A critical evaluation of the Braak staging scheme for Parkinson's disease. Ann Neurol 64: 485-491.
11. Caccamo A, Maldonado MA, Bokov AF, Majumder S, Oddo S (2010) CBP gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 107(52): 22687-22692.
12. Chen PS, Peng GS, Li G, Yang S, Wu X, Wang CC, Wilson B, Lu RB, Gean PW, Chuang DM, Hong JS (2006) Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry 11(12): 1116-1125.
13. Darmopil S, Martín AB, De Diego IR, Ares S, Moratalla R (2009) Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Biol Psychiatry 66(6): 603-613.
14. Dauer W, Przedborski S (2003) Parkinson's disease: mechanisms and models. Neuron 39: 889-909.
15. de Mena L, Coto E, Cardo LF, Díaz M, Blázquez M, Ribacoba R, Salvador C, Pastor P, Samaranch L, Moris G, Menéndez M, Corao A, Alvarez V (2010) Analysis of the Micro-RNA-133 and PITX3 genes in Parkinson's disease. Am J Med Genet B 153B(6): 1234-1239.
16. Desplats P, Spencer B, Coffee E, Patel P, Michael S, Patrick C, Adame A, Rockenstein E, Masliah E (2011) Alpha-synuclein sequesters Dnmt1 from the nucleus: a novel mechanism for epigenetic alterations in Lewy body diseases. J Biol Chem 286(11): 9031-9037.
17. Dolinoy DC, Jirtle RL (2008) Environmental epigenomics in human health and disease. Environ Mol Mutagen 49: 4-8.
18. Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, Mattson MP (2002) Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem 80(1): 101-110.
19. Ertekin-Taner N (2007) Genetics of Alzheimer's disease: a centennial review. Neurol Clin 25: 611-667.
20. Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG (2007) Levodopa-induced dyskinesias. Mov Disord 22(10): 1379-1389.
21. Farrer MJ (2006) Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet 7: 306-318.
22. Finkelstein JD (2000) Pathways and regulation of homocysteine metabolism in mammals. Semin Thromb Hemost 26(3): 219-225.
23. Francis YI, Fà M, Ashrafa H, Zhanga H, Staniszewskia A, Latchmanb DS, Arancioa O (2009) Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer's disease. J Alzheimers Dis 18: 131-139.
24. Frieling H, Gozner A, Römer KD, Lenz B, Bönsch D, Wilhelm J, Hillemacher T, de Zwaan M, Kornhuber J, Bleich S (2007) Global DNA hypomethylation and DNA hypermethylation of the alpha synuclein promoter in females with anorexia nervosa. Mol Psychiatry 12(3): 229-230.
25. Fuso A, Seminara L, Cavallaro RA, D'Anselmi F, Scarpa S (2005) S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. Mol Cell Neurosci 28: 195-204.
26. Fuso A, Nicolia V, Cavallaro RA, Ricceri L, D'Anselmi F, Coluccia P, Calamandrei G, Scarpa S (2008) B-vitamin deprivation induces hyperhomocysteinemia and brain S-adenosylhomocysteine, depletes brain S-adenosylmethionine, and enhances PS1 and BACE expression and amyloid-beta deposition in mice. Mol Cell Neurosci 37(4): 731-746.
27. Fuso A, Nicolia V, Pasqualato A, Fiorenza MT, Cavallaro RA, Scarpa S (2011a) Changes in Presenilin 1 gene methylation pattern in diet-induced B vitamin deficiency. Neurobiol Aging 32(2): 187-199.
28. Fuso A, Nicolia V, Cavallaro RA, Scarpa S (2011b) DNA methylase and demethylase activities are modulated by one-carbon metabolism in Alzheimer's disease models. J Nutr Biochem 22(3): 242-251.
29. Giles WH, Kittner SJ, Anda RF, Croft JB, Casper ML (1995) Serum folate and risk for ischemic stroke. First National Health and Nutrition Examination Survey epidemiologic follow-up study. Stroke 26(7): 1166-1170.
30. Gillardon F, Mack M, Rist W, Schnack C, Lenter M, Hildebrandt T, Hengerer B (2008) MicroRNA and proteome expression profiling in early-symptomatic α-synuclein(A30P)-transgenic mice. Proteomics Clin Appl 2(5): 697-705.
31. Hardy J, Lewis P, Revesz T, Lees A, Paisan-Ruiz C (2009) The genetics of Parkinson's syndromes: a critical review. Curr Opin Genet Dev 19: 254-265.
32. Hébert SS, De Strooper B (2009) Alterations of the microRNA network cause neurodegenerative disease. Trends Neurosci 32(4): 199-206.
33. Jiang Q, Ren Y, Feng J (2008) Direct binding with histone deacetylase 6 mediates the reversible recruitment of parkin to the centrosome. J Neurosci 28(48): 12993-13002.
34. Jowaed A, Schmitt I, Kaut O, Wüllner U (2010) Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains. J Neurosci 30(18): 6355-6359.
35. Junn E, Lee K-W, Jeong BS, Chan TW, J-Y IM, Mouradian MM (2009) Repression of α-synuclein expression and toxicity by microRNA-7. Proc Natl Acad Sci 106(31): 13052-13057.
36. Khandhar SM, Marks WJ (2007) Epidemiology of Parkinson's disease. Dis Mon 53: 200-205.
37. Kilgore M, Miller CA, Fass DM, Hennig KM, Haggarty SJ, Sweatt JD, Rumbaugh G (2010) Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 35(4): 870-880.
38. Klein C, Schlossmacher MG (2007) Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder. Neurology 69: 2093-2104.
39. Kontopoulos E, Parvin JD, Feany MB (2006) α-Synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet 15(20): 3012-3023.
40. Kovalchuk O (2008) Epigenetic research sheds new light on the nature of interactions between organisms and their environment. Environ Mol Mutagen 49: 1-3.
41. Lau LML, Breteler MB (2006) Epidemiology of Parkinson's disease. Lancet Neurol 5: 525-535.
42. Lambert JC, Amouyel P (2007) Genetic heterogeneity of Alzheimer's disease: complexity and advances. Psychoneuroendocrinology 32(1): S62-S70.
43. Lukiw WJ, Zhan Y, Guo Cui J (2008) An NF-κ B-sensitive Micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. J Biol Chem 283: 31315-31322.
44. Maeda T, Guan JZ, Oyama J, Higuchi Y, Makino N (2009) Aging-associated alteration of subtelomeric methylation in Parkinson's disease. J Gerontol A Biol Sci Med Sci 64(9): 949-955.
45. Marques SC, Oliveira CR, Outeiro TF, Pereira CM (2010) Alzheimer's disease: the quest to understand complexity. J Alzheimers Dis 21(2): 373-383.
46. Matsumoto L, Takuma H, Tamaoka A, Kurisaki H, Date H, Tsuji S, Iwata A (2010) CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease. PLoS One 5(11): e15522.
47. Minati L, Edginton T, Bruzzone MG, Giaccone G (2009) Current concepts in Alzheimer's disease: a multidisciplinary review. Am J Alzheimers Dis Other Demen 24: 95-121.
48. Monti B, Gatta V, Piretti F, Raffaelli SS, Virgili M, Contestabile A (2010) Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease: involvement of alpha-synuclein. Neurotox Res 17(2): 130-141.
49. Nicholas AP, Lubin FD, Hallett PJ, Vattem P, Ravenscroft P, Bezard E, Zhou S, Fox SH, Brotchie JM, Sweatt JD, Standaert DG (2008) Striatal histone modifications in models of levodopa-induced dyskinesia. J Neurochem 106(1): 486-494.
50. Obeid R, Schadt A, Dillmann U, Kostopoulos P, Fassbender K, Herrmann W (2009) Methylation status and neurodegenerative markers in Parkinson disease. Clin Chem 55(10): 1852-1860.
51. Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore AM, Volk CB, Maxwell MM, Rochet JC, McLean PJ, Young AB, Abagyan R, Feany MB, Hyman BT, Kazantsev AG (2007) Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 317(5837): 516-519.
52. Pacheco-Quinto J, de Turco EBR, DeRosa S, Howard A, Cruz-Sanchez F, Sambamurti K, Refolo I, Petancesk S, Pappolla MA (2006) Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid B peptide levels. Neurobiol Dis 22: 651-656.
53. Ray WJ, Ashall F, Goate AM (1998) Molecular pathogenesis of sporadic and familial forms of Alzheimer's disease. Mol Med Today 4: 151-157.
54. Ricobaraza A, Cuadrado-Tejedor M, Pérez-Mediavilla A, Frechilla D, Del Río J, García-Osta A (2009) Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model. Neuropsychopharmacology 34(7): 1721-1732.
55. Ricobaraza A, Cuadrado-Tejedor M, Marco S, Pérez-Otaño I, García-Osta A (2010) Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease. Hippocampus 22(5): 1040-1050.
56. Rocchi A, Pellegrini S, Siciliano G, Murri L (2003) Review: causative and susceptibility genes for Alzheimer's disease: a review. Brain Res Bull 61: 1-24.
57. Rouaux C, Jokic N, Mbebi C, Boutillier S, Loeffler JP, Boutillier AL (2003) Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration. EMBO J 22(24): 6537-6549.
58. Schipper HM, Maes OC, Chertkow HM, Wang E (2007) MicroRNA expression in Alzheimer blood mononuclear cells. Gene Regul Syst Biol 20(1): 263-274.
59. Silva PNO, Gigek CO, Leal MF, Bertolucci PHF, de Labio RW, Payão SLM, Smith MAC (2008) Promoter methylation analysis of SIRT3, SMARCA5, HTERT and CDH1 genes in aging and Alzheimer's disease. J Alzheimers Dis 13: 173-176.
60. Song C, Kanthasamy A, Anantharam V, Sun F, Kanthasamy AG (2010) Environmental neurotoxic pesticide increases histone acetylation to promote apoptosis in dopaminergic neuronal cells: relevance to epigenetic mechanisms of neurodegeneration. Mol Pharmacol 77(4): 621-632.
61. Sontag E, Hladik C, Montgomery L, Luangpirom A, Mudrak I, Ogris E, White CL 3rd (2004) Downregulation of protein phosphatase 2A carboxyl methylation and methyltransferase may contribute to Alzheimer disease pathogenesis. J Neuropathol Exp Neurol 63(10): 1080-1091.
62. Sontag E, Nunbhakdi-Craig V, Sontag JM, Diaz-Arrastia R, Ogris E, Dayal S, Lentz SR, Arning E, Bottiglieri T (2007) Protein phosphatase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation. J Neurosci 27: 2751-2759.
63. St George-Hyslop PH, Petit A (2004) Molecular biology and genetics of Alzheimer's disease. Comptes Rendus Biologies 328: 119-130.
64. Stozicka Z, Zilka N, Novak M (2007) Review: risk and protective factors for sporadic Alzheimer's disease. Acta Virol 51: 205-222.
65. Tanzi RE, Bertram L (2001) New frontiers in Alzheimer's disease genetics. Neuron 32: 181-184.
66. Tohgi H, Utsugisawa K, Nagane Y, Yoshimura M, Genda Y, Ukitsu M (1999) Reduction with age in methylcytosine in the promoter region-224-101 of the amyloid precursor protein gene in autopsy human cortex. Mol Brain Res 70: 288-292.
67. Vo N, Klein ME, Varlamova O, Keller DM, Yamamoto T, Goodman RH, Impey S (2005) A cAMPresponse element binding protein-induced microRNA regulates neuronal morphogenesis. Proc Natl Acad Sci 102(45): 16426-16431.
68. Voutsinas GE, Stavrou EF, Karousos G, Dasoula A, Papachatzopoulou A, Syrrou M, Verkerk AJ, van der Spek P, Patrinos GP, Stöger R, Athanassiadou A (2010) Allelic imbalance of expression and epigenetic regulation within the alpha-synuclein wild-type and p. Ala53Thr alleles in Parkinson disease. Hum Mutat 31(6): 685-691.
69. Wang G, van der Walt JM, Mayhew G, Li Y, Zuchner S, Scott WK, Martin ER, Vance JM (2008a) Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of a-synuclein. Am J Hum Genet 82: 283-289.
70. Wang S-C, Oelze B, Schumacher A (2008b) Age-specific epigenetic drift in late-onset Alzheimer's disease. PLoS One 3: e2698.
71. Wang WX, Rajeev BW, Stromberg AJ, Ren N, Tang G, Huang Q, Rigoutsos I, Nelson PT (2008c) The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci 28(5): 1213-1223.
72. Wang X, Liu P, Zhu H, Xu Y, Ma C, Dai X, Huang L, Liu Y, Zhang L, Qin C (2009a) miR-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer's disease, inhibits bcl2 translation. Brain Res Bull 80(4-5): 268-273.
73. Wang Y, Wang X, Liu L, Wang X (2009b) HDAC inhibitor trichostatin A-inhibited survival of dopaminergic neuronal cells. Neurosci Lett 467(3): 212-216.
74. Weintraub D, Comella CL, Horn S (2008) Parkinson's disease-part 1: pathophysiology, symptoms, burden, diagnosis, and assessment. Am J Manag Care 14: S40-S48.
75. Wood-Kaczmar A, Gandhi S, Wood NW (2006) Understanding the molecular causes of Parkinson's disease. Trends Mol Med 12: 521-528.
76. World Health Organization (2002) Active ageing, a policy framework. Second United Nations World assembly on Aging, Madrid, Spain. w ww. who. int/hpr/ageing/ActiveAgingPolicyFrame. pdf.
77. Wu J, Basha MR, Brock B, Cox DP, Cardozo-Pelaez F, McPherson CA, Harry J, Rice DC, Maloney B, Chen D, Lahiri DK, Zawia NH (2008a) Alzheimer's disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): evidence for a developmental origin and environmental link for AD. J Neurosci 28: 3-9.
78. Wu X, Chen PS, Dallas S, Wilson B, Block ML, Wang CC, Kinyamu H, Lu N, Gao X, Leng Y, Chuang DM, Zhang W, Lu RB, Hong JS (2008b) Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int J Neuropsychopharmacol 11(8): 1123-1134.